Portal de Periódicos da CAPES

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes

2020; American College of Physicians; Volume: 173; Issue: 7 Linguagem: Inglês

10.7326/l20-1055

1539-3704

Marko Lucijanić, Miran Lovrinov, Marko Skelin,

Myeloproliferative Neoplasms: Diagnosis and Treatment

Letters6 October 2020Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic SyndromesMarko Lucijanic, MD, PhD, Miran Lovrinov, MPharm, and Marko Skelin, MPharm, PHDMarko Lucijanic, MD, PhDUniversity Hospital Dubrava, Zagreb, Croatia (M.L.), Miran Lovrinov, MPharmMakPharm, Zagreb, Croatia (M.L.), and Marko Skelin, MPharm, PHDGeneral Hospital Sibenik, Sibenik, Croatia (M.S.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1055 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Angelucci and colleagues' article (1) about the clinical benefit of iron chelation therapy (ICT) in iron-overloaded patients with lower-risk myelodysplastic syndromes with interest. A large proportion of patients in the placebo group discontinued therapy (83% did so because of reasons other than death, and 47% did so because of personal decisions) and received subsequent ICT (33%). While interpreting event-free survival (EFS) curves, the authors speculated that the clinical benefit of ICT might have been underestimated because of the comparison with crossover patients who were still shown in the intention-to-treat placebo curve. However, we believe that ...Reference1. Angelucci E, Li J, Greenberg P, et al; TELESTO Study Investigators.. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes. A randomized trial. Ann Intern Med. 2020;172:513-22. [PMID: 32203980]. doi:10.7326/M19-0916 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University Hospital Dubrava, Zagreb, Croatia (M.L.)MakPharm, Zagreb, Croatia (M.L.)General Hospital Sibenik, Sibenik, Croatia (M.S.)Note: Mr. Lovrinov is an employee of MakPharm.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1055. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoIron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes Emanuele Angelucci , Junmin Li , Peter Greenberg , Depei Wu , Ming Hou , Efreen Horacio Montaňo Figueroa , Maria Guadalupe Rodriguez , Xunwei Dong , Jagannath Ghosh , Miguel Izquierdo , Guillermo Garcia-Manero , and Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes Emanuele Angelucci , Peter Greenberg , Miguel Izquierdo , and Guillermo Garcia-Manero Metrics Cited byIron overload disordersPrognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients 6 October 2020Volume 173, Issue 7Page: 595KeywordsDisclosureFerritinIntent to treat analysisMyelodysplastic syndromesSurvival analysis ePublished: 6 October 2020 Issue Published: 6 October 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...